An industry-prioritized GTM for NovintiX — Pharma & Healthcare as Priority-1, MedTech/Diagnostics as the core, and a reach-out motion into Aerospace & Defense, Automotive, Consumer Electronics and Industrial — plus the capabilities to build to sell better.
One engineering muscle, sequenced across industries by fit and speed-to-revenue. NovintiX already sells regulated product engineering into MedTech; Pharma and Healthcare are the fastest adjacent expansions, and the safety-critical industries are a longer reach-out that reuses the same rigor.
NovintiX's transferable asset is evidence-grade engineering for regulated products — design controls, risk management, verification & validation, requirements traceability, and the compliance data regulators and auditors demand. That muscle is industry-agnostic; only the standard changes (FDA/MDR → GxP/GAMP5 → DO-178C → ISO 26262 → IEC 61508).
So the GTM is not "pick an industry" — it's sequence the same capability into the markets where the fit is tightest and the buying trigger is loudest, priced as fixed-scope offers that a team can buy without a bespoke program.
Industry prioritization
Priority-1 is where the regulatory pain is sharpest and the adjacency to today's MedTech work is shortest. The reach-out industries reuse the same safety-critical engineering discipline but need proof and, in some cases, a hire or partner.
PRIORITY 1
Pharma & Healthcare
fastest revenue, tightest adjacency
PharmaGxP/GAMP5 computer-system validation, data integrity (ALCOA+), manufacturing & quality analytics, combination-product (drug-device) design controls, PV & regulatory data engineering.
ThesisSafety-critical & regulated engineering transfers: DO-178C/DO-254, ISO 26262/SOTIF/ASPICE, IEC 61508 all demand the traceability and V&V evidence NovintiX already builds.
ApproachWarm, opportunistic reach-out — one lighthouse account per industry, an adapted offer, and a domain hire or partner before scaling.
Priority-1 · Pharma
Sell the same evidence discipline into GxP-regulated software, data and manufacturing — where the audit stakes are as high as MedTech and the specialist bandwidth is just as short.
ICP
Who to target
Pharma R&D, manufacturing IT/OT, quality, PV & regulatory — in-house teams and their India GCCs (500–5,000 seats).
Economic buyer: Head of Quality/IT/Manufacturing Systems or R&D Engineering
"We build the validation evidence, not just the SOP — audit-ready, on a fixed scope, without pulling your validation team off the line."
Against big SIs: MedTech-grade rigor, not generalist staff-aug
Against QA consultancies: we build & validate, they advise
Proof to build
What unlocks the sale
One CSV/GAMP5 case study with a named outcome
A sample validation-evidence package
GAMP5 / 21 CFR Part 11 mapping accelerator
Priority-1 · Healthcare
Where devices become software and data — SaMD, digital health, interoperability and connected care. NovintiX's SaMD V&V muscle is the wedge; data engineering is the expansion.
ICP
Who to target
Digital-health & health-tech companies, health systems' innovation/IT, payers' data platforms, and their India GCCs.
Economic buyer: VP Digital Health / Head of Product Engineering / CMIO-adjacent IT
Champion: Regulatory/quality lead for SaMD or an interoperability owner
Connected-Health Integration — device-to-cloud data pipelines with quality controls
AI-in-Clinical Validation — model validation & change-control for clinical AI
Messaging
The line that lands
"Digital health only ships when the evidence is ready — we make SaMD and health-data features audit-ready and interoperable."
Against pure dev shops: we bring the regulatory & V&V evidence
Against advisory: we build the pipelines and the proof
Proof to build
What unlocks the sale
A SaMD V&V reference + sample evidence file
A FHIR conformance demo
An AI-in-clinical model-validation template
Reach-out industries — same rigor, adapted
The safety-critical industries buy the identical discipline under a different standard. Reach out opportunistically to one lighthouse account each; win it, then decide whether to hire/partner and scale.
Industry
Why NovintiX can play
Entry wedge (adapted offer)
Needs first
Aerospace & Defense
DO-178C / DO-254 demand the same requirements-to-test traceability & V&V evidence NovintiX builds for devices
Safety-critical V&V & certification-evidence pod for one avionics software/hardware item
A DO-178C-literate engineer or partner; a security/ITAR-aware posture
Automotive
ISO 26262 functional safety, SOTIF and ASPICE mirror device risk-management & V&V — surging with ADAS/EV software
Functional-safety V&V pod for one ADAS/EV software component
An ISO 26262 lead; an automotive reference
Consumer Electronics
Connected/wearable devices increasingly cross into regulated (medical-adjacent) territory — NovintiX's regulatory edge is the differentiator
Wearable / connected-device engineering + regulatory-adjacency review (is this a medical device?)
A consumer-hardware reference; speed/cost-tuned delivery
Industrial & Heavy Equipment
IEC 61508 functional safety + industrial IoT + predictive-maintenance data engineering reuse the safety & data muscle
Functional-safety + industrial-data engineering for one line/asset class
An IEC 61508 reference; OT-data literacy
Rule for reach-out: do not lead generation-scale outreach here yet. One scoped lighthouse per industry, sold on MedTech proof and the transferable rigor. Only after a win do you invest in the domain hire, the certification, or the partner that makes the industry a real line of business.
Cross-industry positioning
Category: "The regulated & safety-critical product-engineering specialist — we build the evidence." One identity across every industry; the standard is a footnote, the discipline is the brand.
The through-line: design controls · risk management · verification & validation · requirements traceability · compliance data. Whether it's a 62304 file, a GAMP5 validation, a DO-178C artefact or an ISO 26262 safety case, it's the same craft.
Why a specialist beats the SI and the boutique: the SI is generalist and priced for transformation; the boutique advises but doesn't build. NovintiX lands fast on one scoped thing and hands back audit-ready evidence — under the client's existing vendor framework.
Capabilities to build to sell better
Selling better is less about more outreach and more about assets that shorten every evaluation: productized offers, proof, reusable IP, and — the compounding move — turning the highest-repeat service into an AI-native product.
Now · 0–6 months
Package & prove
Fixed-scope offer catalogue with published price bands (UDI Sprint, Design-Control Accelerator, SaMD Assurance, CSV Validation Sprint, Engineering Health Check) — so buyers say yes without a bespoke SOW
3–5 written case studies + reference customers + sample artefacts (a redacted DHF, a V&V evidence set, a UDI record pack) to hand a technical evaluator
Per-industry capability decks + ROI one-pagers and an outbound cadence per ICP
Now · 0–6 months
Credibility & access
Own ISO 13485 / a quality system for NovintiX itself — proof you live the discipline
Notified-body & UDI-platform relationships; cloud/tooling partnerships for co-sell
Thought-leadership engine: a regulatory-intelligence newsletter + executive roundtables (the convener channel)
Next · 6–18 months
Productize & scale delivery
AI-native product from the most-repeated service — test-proof / V&V-evidence management → ProofX (see the ProofX launch plan)
Domain accelerators: pre-built compliance frameworks & mappings per standard, sold as IP
Delivery playbooks + associate-engineer enablement so standardized offers run without founder time
Data & analytics capability for manufacturing-quality and PV
Later · 18 months+
Platform & footprint
A small product portfolio (ProofX + one adjacent tool) — recurring revenue alongside services
Retained-pod / managed-service model at scale as base-load revenue
Onshore regulatory presence (US/EU) and multi-geo delivery for global GCC buyers
Ecosystem positioning: integrate with eQMS/ALM vendors; selective hire/partner/M&A for automotive & aerospace adjacency
Channels & motion
Land in the core (MedTech), expand into P1. Every MedTech win is a reference that opens a Pharma or Healthcare conversation about the same evidence problem under a different standard.
Founder-led + convener. Peer-to-peer outreach to the economic buyer and champion, plus small standards-themed roundtables ("Design Controls & UDI", "GxP Data Integrity", "SaMD V&V") to earn access across several accounts at once.
GCC corridor as a force multiplier. The India MedTech/pharma/healthcare GCCs concentrate the buyers — the flagship GCC-penetration motion (see the NovintiX GCC example) is the account-selection and buying-center engine for all three P1 segments.
Reference-led expansion. Case studies do the selling in a risk-averse market — invest in capturing and publishing them from day one.
The plans — 30, 90, 180 days and 1 year
Sequenced to package the core, open Priority-1 (Pharma & Healthcare), then productize and probe the reach-out industries. Each horizon has a goal, work items and hard exit criteria.
30 days
Package the core, open Pharma & Healthcare
Goal. Turn today's MedTech capability into a sellable catalogue and open the two Priority-1 segments.
Offer cataloguePublish fixed-scope offers with price bands for MedTech + a CSV/GAMP5 Sprint (Pharma) and a SaMD Assurance Pack (Healthcare).
Proof kitDraft the first MedTech case study and assemble sample artefacts (redacted DHF, V&V evidence, UDI records).
Target listsBuild P1 account lists — pharma quality/manufacturing GCCs and digital-health/health-system targets — with buying-center roles.
First touchesLaunch founder-led cadences into 3 Pharma + 3 Healthcare accounts, each on a specific trigger (audit, EUDAMED, SaMD review, FHIR mandate).
ConvenerDate a "GxP Data Integrity & SaMD V&V" roundtable.
Exit criteria. Offer catalogue live, 6 P1 accounts in active cadence, first case study drafted, roundtable dated.
90 days
First P1 wins + credibility assets
Goal. Land the first Pharma and Healthcare micro-pilots and stand up the credibility assets that shorten the next sale.
Land P1Close 1 Pharma (CSV/GAMP5) and 1 Healthcare (SaMD/FHIR) micro-pilot on a fixed scope.
Proof enginePublish 2–3 case studies; capture references; ship the per-industry capability decks + ROI one-pagers.
IPPackage the first accelerators (GAMP5 & 62304 mapping checklists, validation harness) as reusable assets.
Quality systemKick off ISO 13485 / internal QMS and open notified-body + UDI-platform partner conversations.
Reach-out probeWarm-intro one Aerospace or Automotive lighthouse to test the safety-critical adjacency.
Exit criteria. 2 P1 pilots delivered/closed, 3 case studies live, accelerators packaged, QMS underway, 1 reach-out probe open.
180 days
Expand P1 + start productizing
Goal. Grow P1 into repeatable revenue and begin turning the most-repeated service into a product.
ExpandConvert the first P1 wins into device-family / system-wide engagements; open retained-pod conversations.
RepeatabilityStandardize the top offers with delivery playbooks so associate engineers run them without founder time.
ProductizeScope the AI-native product (ProofX) from the V&V/test-proof service; start the MVP (see ProofX plan).
Roadmap the reach-outIf the lighthouse probe landed, hire/partner for that domain (ISO 26262 or DO-178C) and build one adapted offer.
Thought leadershipRun the roundtable series; ship the regulatory-intelligence newsletter monthly.
Goal. Establish NovintiX as the go-to regulated-engineering specialist across MedTech + Pharma + Healthcare, with a productized edge and a foothold in one reach-out industry.
Balanced bookRevenue across MedTech (core), Pharma and Healthcare; 1–2 retained pods as base load.
ProductProofX in market with early customers — recurring revenue alongside services.
Reach-outOne safety-critical industry (automotive or aerospace) with a first reference and an adapted offer.
IP & brandA published accelerator/framework library; a recognized voice on regulated-product evidence.
Delivery enginePlaybooks + associates run standardized offers; founders focus on new-logo landing, product and expansion.
2 (Pharma+Healthcare)
Priority-1 segments live
5+
Productized offers
5–7
Case studies / references
1–2
Retained pods
1 (ProofX)
AI-native products
1
Reach-out references
Exit criteria. 3-segment revenue balance, ProofX live with customers, 1 reach-out reference, retained pods, a scalable delivery engine.
Directional GTM research aid built on public information about NovintiX and its stated industries (medical devices, life sciences & healthcare, aerospace & defense, automotive, consumer electronics, industrial & heavy equipment). Prioritization and sequencing are recommendations, not commitments; validate against NovintiX's actual capacity, references and appetite before acting. Not affiliated with any named company.